Abbott First To Offer OTC Continuous Glucose Monitor On Amazon

Abbott is now offering its consumer CGM Lingo at Amazon for $49 for a single sensor. Its rival Dexcom also expects to introduce its consumer CGM Stelo on Amazon in Q1.

Lingo
Lingo prototype sensor with screen of smartphone app Abbott shared with its January 2022 announcement of the product's development. • Source: Abbott

Abbott recently announced a deal with retail giant Amazon to offer its over-the-counter glucose monitor (CGM) for people without diabetes wanting to track their glucose levels to improve their metabolic health.

Key Takeaways
  • Abbott now offers its consumer CGM device Lingo on Amazon for $49 for the single sensor, which can work up to 14 days.

The company announced the deal on 25 February. Lingo, which is based on Abbott’s existing FreeStyle Libre diabetes monitoring platform,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Medtech Insight

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.

Digital Health Roundup: Autonomous Robots, Medtronic’s Surgeon School, Sleep & FDA Rules

In this week's Digital Health Roundup, Medtech Insight's team discusses progress on autonomous surgery, Medtronic's new partnership with IRCAD, FDA cybersecurity news, and C-suite interviews with OpenWater, Flow Neuroscience and EnsoData.

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.

More from Digital Technologies